Syneos Health Signs Agreement with Aotearoa Clinical Trials, Further Expanding Catalyst Site Program in New Zealand
August 10, 2023
MORRISVILLE, N.C. – August 10, 2023 – Syneos Health® (Nasdaq:SYNH) a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with Aotearoa Clinical Trials, expanding the Company’s clinical trial capabilities across a broad range of therapeutic areas in New Zealand, including Oncology, General Medicine and Vaccines.
Aotearoa Clinical Trials now joins the Syneos Health Catalyst Site Program, which was introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The Program harnesses insights from sites across the globe to drive continuous improvement and develop best practices in clinical research delivery.
Together, Syneos Health and Aotearoa Clinical Trials will enable sites, sponsors and patients to collaborate in multiple therapeutic areas, fueling engagement through transparent communication channels during the entire clinical trial process.
“Our work with Aotearoa Clinical Trials enables us to provide customized solutions that address our customers’ unique and complex needs,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “We look forward to collaborating with Aotearoa Clinical Trials as part of the Catalyst Site Program.”
Syneos Health has relationships with more than 100 Catalyst sites worldwide and the Company has been acknowledged by the Society for Clinical Research Sites as a recipient of the Eagle Award for demonstrating dedication to establishing strong site partnerships.
Dr. Edward Watson CEO at Aotearoa Clinical Trials welcomed the signature of the agreement: “We are excited to be part of the Catalyst Site Program which will enable more clinical trials to be performed in New Zealand and provide more options for clinical trial participation in our communities.”
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
About Aotearoa Clinical Trials
Aotearoa Clinical Trials Trust is an independent charitable trust that specializes in running both commercial (Phase I to III) and grant funded trials (investigator initiated and collaborative group trials) in partnership with public hospitals in New Zealand. Aotearoa Clinical Trials has over 20 years of experience as an integrated specialist clinical trial site, which produces high quality data in collaboration with hospital clinicians across multiple therapeutic areas.
Aotearoa Clinical Trials aims to reduce inequity in healthcare to communities of Aotearoa - New Zealand, by providing access of global innovative therapies through clinical trials.
Syneos Investor Relations Contact: Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 [email protected] | Syneos Press/Media Contact: Gary Gatyas Executive Director, External Communications +1 908 763 3428 [email protected] |